Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. has announced a differentiated cash dividend distribution plan, with a proposed cash dividend of 0.25 RMB per share, approved at the 2024 annual general meeting on May 13, 2025 [2][8]. Dividend Distribution Plan - The company plans to distribute a cash dividend of 2.50 RMB for every 10 shares held, amounting to a total cash dividend of 62.54 million RMB based on the adjusted total share capital of 250,115,693 shares, excluding 496,600 shares held in the repurchase account [2][3]. - The cash dividend will be distributed to all shareholders registered by the end of the trading day on the record date, with the payment date to be announced later [2][5]. Tax Implications - For individual shareholders holding unrestricted shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.25 RMB per share [6][7]. - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution, but tax will be calculated upon the sale of shares [6][7]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.225 RMB per share [7][8]. Implementation Details - Shares held in the company's repurchase account will not participate in the profit distribution [2][5]. - The reference price for ex-dividend trading will be calculated based on the previous closing price minus the cash dividend, with no change in the number of circulating shares [3][5].

兴业证券股份有限公司 关于安徽华恒生物科技股份有限公司 差异化权益分派事项的核查意见 兴业证券股份有限公司（以下简称"兴业证券"或"保荐机构"）作为安徽华恒 生物科技股份有限公司（以下简称"华恒生物"或"公司"）向特定对象发行 A 股股 票的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》《证 券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海 证券交易所上市公司自律监管指引第 7 号——回购股份》以及《上海证券交易所 上市公司自律监管指南第 2 号——业务办理》等法律、法规和规范性文件的要 求，对华恒生物 2024 年度利润分配所涉及的差异化权益分派事项进行了核查， 核查情况及核查意见如下： 一、本次差异化权益分派的原因 2023年8月11日，公司召开第四届董事会第六会议，审议通过了《关于以集 中竞价交易方式回购公司股份的议案》，同意公司以自有资金通过上海证券交易 所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股 票，本次回购的股份将在未来适宜时机全部用于股权激励，回购价格不超过133 元/股（含），回购资金总额不低于人民币3,000万元（含），不超过 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-029 安徽华恒生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/9 | 2025/7/10 | 2025/7/10 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经安徽华恒生物科技股份有限公司（以下简称"公司"）2025 年 5 月 13 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 1 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.25元 相关日期 号——回购股份》等有关规定，上市公 ...

Core Viewpoint - The stock of Huaheng Biological (688639) is currently showing a weak performance with a comprehensive score of 49.43, indicating a need for cautious observation as it has broken through short-term support levels [1][2][3] Group 1: Stock Performance - The stock's current price is 31.41 CNY, with a short-term support level at 31.69 CNY and a short-term resistance level at 33.00 CNY [2] - Over the past year, the stock has not experienced any limit-up or limit-down events [1] - The stock has a recent net outflow of 15.71 million CNY from main funds, accounting for 18% of the total trading volume [2][3] Group 2: Financial Data - The latest financial report indicates earnings per share of 0.2 CNY and an operating profit of 0.55 billion CNY [2][3] - The gross profit margin stands at 24.308%, with a net profit of approximately 49.14 million CNY [2][3] Group 3: Market Sentiment - The stock has seen a slight increase in northbound capital holdings, with a total of 1.7943 million shares held, representing 0.78% of the circulating shares [1] - The recent buying activity shows a net increase of 0.94 million shares yesterday, with a 5-day increase ratio of 0.03% and a 20-day increase ratio of 0.174% [1]

兴业证券股份有限公司 关于安徽华恒生物科技股份有限公司 核心技术人员离职的核查意见 兴业证券股份有限公司（以下简称"兴业证券"或"保荐机构"）作为安徽华 恒生物科技股份有限公司（以下简称"华恒生物"或"公司"）向特定对象发行 A 股股票的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券 法》《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规 则》等法律、法规和规范性文件的要求，对华恒生物核心技术人员离职事项进 行了核查，核查情况及核查意见如下： 一、核心技术人员离职的具体情况 邓杰勇先生因个人原因与公司协商一致解除劳动关系，离职后不再担任公 司任何职务。邓杰勇先生在公司任职期间恪尽职守、勤勉尽责，公司对邓杰勇 先生在任职期间为公司发展所做出的努力和贡献表示衷心感谢。 （一）核心技术人员的具体情况 邓杰勇先生，1990 年生，中国国籍，无境外永久居留权，毕业于合肥工业 大学生物工程专业，硕士学历；2016 年 6 月至 2017 年 5 月，任公司技术部管理 培训生，2017 年 11 月至今历任秦皇岛华恒生产二部副经理、秦皇岛华恒高级 经理等职务。 根据公司与邓杰勇先生签署的《保密及竞 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-028 安徽华恒生物科技股份有限公司 关于核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、核心技术人员离职的具体情况 邓杰勇先生因个人原因与公司协商一致解除劳动关系，离职后不再担任公司 任何职务。邓杰勇先生在公司任职期间恪尽职守、勤勉尽责，公司对邓杰勇先生 在任职期间为公司发展所做出的努力和贡献表示衷心感谢。 （一）核心技术人员的具体情况 邓杰勇先生，1990年生，中国国籍，无境外永久居留权，毕业于合肥工业大 学生物工程专业，硕士学历；2016年6月至2017年5月，任公司技术部管理培训生， 2017年11月至今历任秦皇岛华恒生产二部副经理、秦皇岛华恒高级经理等职务。 截至本公告披露之日，邓杰勇先生直接持有公司 16,431 股股份，占公司总 1 安徽华恒生物科技股份有限公司（以下简称"公司"）核心技术 人员邓杰勇先生因个人原因与公司协商一致解除劳动关系，离职 后不再担任公司任何职务。 公司与邓杰勇先生签署了《保密及竞业 ...

Core Insights - Company reported a contradictory financial performance for 2024, with revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, but a net profit of 190 million yuan, down 57.8% [2] - The company addressed key regulatory concerns regarding overseas revenue authenticity, sharp decline in gross margin, and abnormal inventory growth in a detailed response to the Shanghai Stock Exchange [2][3] Revenue and Market Performance - The company achieved overseas revenue exceeding 1 billion yuan for the first time, reaching 1.032 billion yuan, accounting for 47.39% of total revenue, with a year-on-year growth of 30.34% [3] - The European market was the primary source of overseas revenue, contributing 429 million yuan, while the Americas and Asia accounted for 294 million yuan and 309 million yuan, respectively [3] - The growth in revenue was primarily supported by the top five overseas customers, whose sales reached 418 million yuan, an increase of 111 million yuan from the previous year [3] Pricing Pressure and Gross Margin Decline - The company acknowledged significant price declines due to intensified market competition, particularly for L-valine, leading to a sharp drop in average selling prices for amino acids and vitamins [4][5] - The average selling price of amino acid products fell from 19,000 yuan per ton in 2023 to 15,600 yuan per ton in 2024, a decrease of 17.89%, while vitamin products saw a 54.09% drop from 84,300 yuan per ton to 38,700 yuan per ton [4] - The gross margin plummeted from 40.52% to 24.92%, a decline of 15.6 percentage points, raising concerns from the Shanghai Stock Exchange [4] Inventory and Financial Indicators - The company's inventory value surged to 407 million yuan, an increase of 80.09% year-on-year, attributed to increased stock of goods and raw materials [5][6] - Inventory turnover rate decreased from 6.37 times to 5.16 times, indicating a potential risk of impairment due to high inventory levels amid declining prices [5][6] Expansion and Future Projects - Despite the challenges, the company is aggressively expanding its production capacity, with construction projects valued at 1.592 billion yuan, including a 50,000-ton bio-based succinic acid project and a 50,000-ton bio-based propylene glycol project [7] - The company anticipates that these projects will begin operations in the second half of 2025, although there are concerns about the timely realization of benefits from these investments [8] Strategic Initiatives - The company is pursuing collaborations to enhance its supply chain, including forming a "Bio-based Polyester Textile Industry Alliance" and signing strategic agreements with BASF for product development [9] - Additionally, the company secured a 20-year exclusive license for the bio-based production of tryptophan technology from Eurobio [10]

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. reported a significant increase in overseas revenue for 2024, driven primarily by growth in amino acid product sales and the introduction of new products [2][19]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][19]. - The breakdown of overseas revenue shows that the main business revenue increased by 30.34% to 1.032 billion yuan, while other business revenue rose by 88.86% to 40.65 million yuan [2][5]. - The primary regions for overseas sales include Europe, America, and Asia, with varying gross profit margins due to differences in product structure [5][19]. Group 2: Audit Procedures and Findings - The annual audit firm conducted thorough procedures to verify the authenticity and accuracy of overseas revenue, including internal control evaluations and document checks [7][8]. - The audit confirmed that 74.73% of overseas revenue was verified through customer confirmations, indicating a high level of reliability in reported figures [9][21]. - The audit also matched overseas sales data with third-party data, such as export tax refund claims and foreign exchange management bureau data, revealing minimal discrepancies [11][12]. Group 3: Gross Margin Analysis - The company's overall gross margin for 2024 was reported at 24.92%, a decline of 15.60 percentage points from the previous year, primarily due to decreased margins in amino acid and vitamin products [21][22]. - The average selling prices for amino acids and vitamins fell significantly, with L-valine prices dropping by 17.89% and vitamin prices by 54.09% [23][24]. - The decline in gross margins is attributed to increased competition and market dynamics, with the company implementing measures to address these challenges [27][35]. Group 4: Future Outlook and Industry Trends - The demand for amino acids is expected to grow due to trends in precision nutrition and reduced reliance on traditional feed ingredients, which may positively impact future margins [27][29]. - The global market for biosynthetic vitamins is projected to grow significantly, indicating potential opportunities for the company as it expands its product offerings [29][30]. - The company is positioned to benefit from technological advancements in production processes, which may enhance cost efficiency and product competitiveness in the long term [31][32].

Core Viewpoint - The company reported a significant increase in overseas revenue for 2024, driven primarily by the growth in amino acid product sales and the introduction of new products, despite a decline in overall gross margin due to competitive pricing pressures in the market [2][18]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][3]. - The main contributors to the overseas revenue growth were the amino acid series products, particularly L-valine, and the vitamin series products, which saw increased sales volumes [5][18]. - The company’s overseas sales were primarily concentrated in Europe (41.58%), the Americas (28.51%), and Asia & others (29.91%) [3][4]. Group 2: Gross Margin Analysis - The overall gross margin for the company in 2024 was reported at 24.92%, a decrease of 15.60 percentage points compared to the previous year [18]. - The gross margin for amino acid products was 30.00%, down 13.32 percentage points, while the vitamin products experienced a more significant decline [18][19]. - The decline in gross margin was attributed to lower average selling prices for key products such as L-valine and myo-inositol, which saw price drops of 17.89% and 54.09% respectively [19][20]. Group 3: Future Outlook and Industry Trends - The demand for amino acids is expected to continue growing due to trends in precision nutrition and the reduction of traditional feed ingredients like soybean meal [23][24]. - The global market for biosynthetic vitamins is projected to grow significantly, with a compound annual growth rate of 9.32% from 2024 to 2030, driven by advancements in synthetic biology [24]. - The company is positioned to benefit from its technological advantages in fermentation processes, which are more environmentally friendly and cost-effective compared to traditional methods [27][28].

上海证券交易所： 兴业证券股份有限公司 关于安徽华恒生物科技股份有限公司 2024年年度报告的信息披露监管问询函回复的核查意见 根据贵所出具的《关于安徽华恒生物科技股份有限公司 2024 年年度报告的 信息披露监管问询函》（上证科创公函【2025】0239 号）（以下简称"年报问 询函"）的要求，兴业证券股份有限公司（以下简称"持续督导机构"）作为 安徽华恒生物科技股份有限公司（以下简称"华恒生物"或"公司"）持续督 导机构，会同公司及容诚会计师事务所（特殊普通合伙），就年报问询函提及 的事项逐项进行了审慎核查，并出具核查意见如下： 本回复报告中若合计数与各分项数值相加之和在尾数上存在差异均为四舍 五入所致。鉴于公司回复内容中披露的部分信息涉及商业秘密，因此公司针对 该部分内容进行了豁免披露。 1、关于海外收入 年报披露，公司 2024 年海外收入 10.32 亿元，占比 47.39%，同比增长 30.34%。请公司：（1）分地区列示 2024 年公司海外各区域收入金额、占比及 毛利率，并说明主要增长原因。（2）请年审会计师说明对境外收入的审计程 序及其充分性、有效性，包括但不限于境外客户的函证与走访具体情况 ...